[Apolipoprotein A-I can be a new tool in the treatment of atherosclerosis].
Five weekly infusions of apolipoprotein A-IMilano/phospholipid complex decreased mean percent coronary atheroma volume as estimated with intravascular ultrasound. The mechanism of action may be through reverse cholesterol transport or through an anti-inflammatory effect. Treatment with high-dose atorvastatin during 18 months did not decrease percent coronary atheroma volume as measured with the same technique. Large-scale efficacy and safety studies will be necessary in order to establish apolipoprotein A-I as the next tool to fight coronary heart disease. The study is in line with the cholesterol hypothesis.